IHT Wealth Management LLC bought a new position in shares of Sanofi SA (NYSE:SNY) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 4,496 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Sage Rhino Capital LLC increased its holdings in Sanofi by 4.5% in the third quarter. Sage Rhino Capital LLC now owns 5,608 shares of the company’s stock valued at $260,000 after buying an additional 243 shares in the last quarter. ERTS Wealth Advisors LLC increased its stake in Sanofi by 3.0% in the 2nd quarter. ERTS Wealth Advisors LLC now owns 8,844 shares of the company’s stock valued at $383,000 after purchasing an additional 259 shares in the last quarter. GWM Advisors LLC increased its stake in Sanofi by 3.7% in the 2nd quarter. GWM Advisors LLC now owns 7,810 shares of the company’s stock valued at $338,000 after purchasing an additional 277 shares in the last quarter. First Allied Advisory Services Inc. increased its stake in Sanofi by 1.6% in the 3rd quarter. First Allied Advisory Services Inc. now owns 17,580 shares of the company’s stock valued at $815,000 after purchasing an additional 277 shares in the last quarter. Finally, Profund Advisors LLC raised its holdings in Sanofi by 1.4% during the second quarter. Profund Advisors LLC now owns 20,499 shares of the company’s stock worth $887,000 after purchasing an additional 283 shares during the last quarter. Institutional investors own 7.04% of the company’s stock.

In other Sanofi news, major shareholder Sanofi sold 172,904 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.00% of the stock is owned by company insiders.

A number of analysts have commented on the company. Morgan Stanley upgraded Sanofi from an “equal” rating to a “weight” rating in a research report on Friday, September 20th. Sanford C. Bernstein began coverage on shares of Sanofi in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $52.00 price objective on the stock. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research report on Thursday, August 29th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, October 14th. Finally, UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $50.33.

SNY opened at $45.55 on Wednesday. The firm has a market cap of $114.06 billion, a P/E ratio of 14.55, a PEG ratio of 2.41 and a beta of 0.67. The business’s fifty day simple moving average is $46.12 and its 200 day simple moving average is $43.87. Sanofi SA has a 52 week low of $40.00 and a 52 week high of $47.47. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40.

Sanofi (NYSE:SNY) last announced its earnings results on Thursday, October 31st. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.11. The firm had revenue of $10.56 billion during the quarter, compared to the consensus estimate of $10.62 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. As a group, equities analysts expect that Sanofi SA will post 3.1 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: Capital Gains Distribution

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.